Mark T. Iwicki - Feb 21, 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Chief Executive Officer, Director
Signature
/s/ Garth Lees-Rolfe, attorney-in-fact
Stock symbol
IKT
Transactions as of
Feb 21, 2025
Transactions value $
$0
Form type
4
Date filed
2/25/2025, 04:05 PM
Previous filing
Feb 19, 2025
Next filing
Feb 26, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +602K $0.00 602K Feb 21, 2025 Common Stock 602K $2.23 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 21, 2025, subject to the Reporting Person's continued employment through such date.